Cancer chemoprevention: A clinical reality

Cantor D . Cancer. In: Bynum WF , Porter R , eds. Companion Encyclopedia of the History of Medicine, Vol. 1. London: Routledge, 1993: 552

Tattersall MHN , Thomas H . Recent advances: Oncology. BMJ 1999; 318: 445–8

Sporn MB , Suh N . Chemoprevention of cancer. Carcinogenesis 2000; 21: 525–30

Gescher AJ , Pastorino U , Plummer SM , Manson MM . Suppression of tumour development by substances derived from the diet-mechanisms and clinical implications. Br] Clin Pharmacol 1998; 45: 1–12

Sporn MB , Newton DL . Chemoprevention of cancer with retinoids. Fed Proc 1979; 38: 2528–34

De Flora S , Balansky R , Scatolini L . Adducts to nuclear DNA and mitochondrial DNA as biomarkers in chemoprevention. In: Stewart BW , McGregor D , Kleihues P , eds. Principles of Chemoprevention. Lyon: IARC, 1996: 291–301

Chemoprevention Working Group. Prevention of cancer in the next millennium. Cancer Res 1999; 59: 4743–58

Israel L , Breau JL , Morere JF , Boaziz C . Evaluation of the antiprostaglandin agent piroxicam in 87 patients with advanced cancer. Sem Hôp 1993; 69: 1293–7

Carbone PP , Douglas JA , Larson PO . Phase I chemoprevention study of piroxicam and α-difluoromethylornithine. Cancer Epid Biomarkers Prev 1998; 7: 907–12

Ripple GH , Gould MN , Bailey HH . Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 2000; 6: 390–6

Fearon ER , Vogelstein B . A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–67

Nowell PC . The clonal evolution of tumour cell populations. Science 1976; 194: 23–8

Fisher B , Costantino JP , Wickerham DL , Redmond CK , Kavanah M , Cronin WM . Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 1998; 90: 1371–88

Cummings SR , Eckert S , Krueger KA , Grady D , Costa A , Jordan VC . The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189–97

Veronesi U , Maisonneuve P , Costa A , Robertson C , Boyle P . Prevention of breast cancer with tamoxifen. Lancet 1998; 352: 93–7

Powles T , Eeles R , Ashley S , Viggers J , Davey J . Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101

The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029–35

Omenn GS , Goodman GE , Thornquist MD , Balmes J , Cullen MR , Glass A . Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J Natl Cancer Inst 1996; 88: 1550–9

Hong WK , Lippman SM , Itri LM , Karp DD , Lee JS , Byers RM . Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795–801

Pastorino U , Infante M , Maioli M . Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clm Oncol 1993; 11: 1216–22

Veronesi U , de Palo G , Marubini E , Costa A , Malone WF , Sporn MB . Randomised trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91: 1847–56

Gottardis MM , Bischoff ED , Shirley MA , Heyman RA . Chemoprevention of mammary carcinoma by LGD1069, an RXR-selective ligand. Cancer Res 1996; 56: 5566–70

Midgely R , Kerr D . Colorectal cancer. Lancet 1999; 353: 391–9

Giardiello FM , Hamilton SR , Krush AJ , Piantadosi S , Hylind LM , Celano P . Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313–16

Smigel K . Arthritis drug approved for polyp prevention blazes trail for other prevention trials. J Natl Cancer Inst 2000; 92: 297

Thun MJ , Namboodiri MM , Health CW Jr . Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–6

Giovannucci E , Rimm EB , Stampfer MJ , Colditz GA , Ascherio A , Willett WC . Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241–6

Collet J-P , Sharpe C , Belzile E , Boivin J-F , Hanley J , Abenhaim L . Colorectal cancer prevention by non-sterodial anti-inflammatory drugs: Effects of dosage and timing. Br J Cancer 1999; 81: 62–8

Plummer SM , Holloway KA , Manson MM . Inhibition of cyclooxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kB activation via the NIK/ IKK signalling complex. Oncogene 1999; 18: 6012–20

Krishnan K , Ruffin MT , Brenner DE . Colon cancer chemoprevention: Clinical development of aspirin as a chemopreventive agent. J Cell Biochem 1997; 28/29 (suppl): 148–58

Van Lieshout EMM , Tiemessen DM , Roelofs HMJ , Peters WHM . Nonsteroidal anti-inflammatory drugs enhance glutathione S-transferase theta levels in rat colon. Biochim Biophys Acta 1998; 1381: 305–11

Szarka CE , Pfeiffer GR , Hum ST , Everley LC , Balshem AM , Moore DF . Glutathione S-transferase activity and glutathione S-transferase μ expression in subjects with risk for colorectal cancer. Cancer Res 1995; 55: 2789–93

Hittelman WM , Papadimetrakopoulou V , Naggar AKE . High genetic instability is associated with poor therapeutic outcome following biochemopreventive treatment of advanced premalignant lesions of the larynx and oral cavity. Proc Am Assoc Cancer Res 2000; 41: 223